Interplay between PCOS and microbiome : The road less travelled
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
Polycystic ovarian syndrome (PCOS) is a complicated neuro-endocrinal, reproductive, and metabolic condition. It encompasses patterns such as hyperandrogenism, recurrent cysts triggered by steroidogenic functional aberrations in the ovaries, overweight, chronic inflammation, and more. The underlying cause of this heterogeneous illness is obscure, although it is suspected to be driven by a blend of environmental and hereditary factors. In recent years, the connection between the microbiome and PCOS has been acknowledged and is thought to be involved in the genesis of the syndrome's emergence. Microbiota vary in different pathological features of PCOS, and fundamental pathways linked to their involvement in the commencement of diverse clinical presentations in PCOS open up a new avenue for its management. Prebiotic, probiotic, synbiotic, and fecal-microbiota-transplant, by promoting eubiosis and nullifying the effect caused by the altered microbial profile in PCOS women, can aid in management of diverse phenotypes associated with the syndrome. These microbiota-mediated treatments improve PCOS women's metabolic, inflammatory, and hormonal profiles. However, more studies are needed to elucidate the mechanisms that drive this positive effect.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:88 |
|---|---|
| Enthalten in: |
American journal of reproductive immunology (New York, N.Y. : 1989) - 88(2022), 2 vom: 10. Aug., Seite e13580 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Batra, Manya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Inflammation |
|---|
| Anmerkungen: |
Date Completed 15.07.2022 Date Revised 27.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/aji.13580 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341208612 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341208612 | ||
| 003 | DE-627 | ||
| 005 | 20231226011243.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/aji.13580 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341208612 | ||
| 035 | |a (NLM)35598286 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Batra, Manya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interplay between PCOS and microbiome |b The road less travelled |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.07.2022 | ||
| 500 | |a Date Revised 27.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a Polycystic ovarian syndrome (PCOS) is a complicated neuro-endocrinal, reproductive, and metabolic condition. It encompasses patterns such as hyperandrogenism, recurrent cysts triggered by steroidogenic functional aberrations in the ovaries, overweight, chronic inflammation, and more. The underlying cause of this heterogeneous illness is obscure, although it is suspected to be driven by a blend of environmental and hereditary factors. In recent years, the connection between the microbiome and PCOS has been acknowledged and is thought to be involved in the genesis of the syndrome's emergence. Microbiota vary in different pathological features of PCOS, and fundamental pathways linked to their involvement in the commencement of diverse clinical presentations in PCOS open up a new avenue for its management. Prebiotic, probiotic, synbiotic, and fecal-microbiota-transplant, by promoting eubiosis and nullifying the effect caused by the altered microbial profile in PCOS women, can aid in management of diverse phenotypes associated with the syndrome. These microbiota-mediated treatments improve PCOS women's metabolic, inflammatory, and hormonal profiles. However, more studies are needed to elucidate the mechanisms that drive this positive effect | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a PCOS | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a metabolites | |
| 650 | 4 | |a microbial-mediated therapy | |
| 650 | 4 | |a microbiota | |
| 700 | 1 | |a Bhatnager, Richa |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Anil |e verfasserin |4 aut | |
| 700 | 1 | |a Suneja, Pooja |e verfasserin |4 aut | |
| 700 | 1 | |a Dang, Amita Suneja |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of reproductive immunology (New York, N.Y. : 1989) |d 1990 |g 88(2022), 2 vom: 10. Aug., Seite e13580 |w (DE-627)NLM012641731 |x 1600-0897 |7 nnns |
| 773 | 1 | 8 | |g volume:88 |g year:2022 |g number:2 |g day:10 |g month:08 |g pages:e13580 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/aji.13580 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 88 |j 2022 |e 2 |b 10 |c 08 |h e13580 | ||